Drug Profile


Alternative Names: MVA-BN RSV; MVA-mBN294B; Respiratory syncytial virus vaccine - Bavarian Nordic

Latest Information Update: 27 Feb 2017

Price : $50

At a glance

  • Originator Bavarian Nordic
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Respiratory syncytial virus infections

Most Recent Events

  • 23 Feb 2017 Updated immunogenicity data from a phase I trial in Respiratory syncytial virus infections released by Bavarian Nordic
  • 14 Dec 2016 Bavarian Nordic completes enrolment in its phase II trial for Respiratory syncytial virus in USA
  • 09 Nov 2016 Bavarian Nordic plans a phase IIb trial for Respiratory syncytial virus infections in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top